Showing 1-10 of about 77 articles.
Otonomy, Inc.
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy, Inc.
OTO-413 demonstrated a higher proportion of responders than placebo based on multiple speech-in-noise hearing testsA single intratympanic injection of OTO-413 was well-tolerated Otonomy intends to...
Starkey Hearing Technologies
Eden Prairie, Minnesota, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Starkey’s ground-breaking technology continues to receive high-profile accolades, this time from the Consumer Technology Association, one...
Otonomy, Inc.
FDA’s review confirms use of Negative Binomial model for analysis of primary endpoint in ongoing OTIVIDEX Phase 3 trial in Ménière’s disease; results still expected in first quarter of 2021Company...
CaptionCall, LLC
SALT LAKE CITY, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Today, CaptionCall announced a new communication feature that allows its captioned telephone service to function without a landline or home internet...
Otonomy, Inc.
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
CaptionCall, LLC
SALT LAKE CITY, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Today, CaptionCall honors America’s military members, veterans, and their families who have answered the call to serve. Currently, there are about...
Otonomy, Inc.
Enrollment completed in Phase 3 clinical trial of OTIVIDEX® in Ménière’s disease with results expected in the first quarter of 2021Positive results reported for Phase 1/2 clinical trial of OTO-313 in...
Otonomy, Inc.
SAN DIEGO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy, Inc.
SAN DIEGO, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Showing 1-10 of about 77 articles.
